At the start of 2020 thousands of biotechies anticipated spending the second week of June in San Diego, hobnobbing at the annual conference hosted by the Biotechnology Innovation Organization.
Instead, attendees from 64 countries spanning 28 times zones convened online this week... Read more »
Diabetes drug giant Novo Nordisk has reached a $725 million deal to acquire Corvidia Therapeutics, a clinical-stage biotech developing treatments for disorders affecting the heart and the kidneys.
The upfront payment due to Corvidia shareholders is cash. According to the... Read more »
Less than a month after reporting preliminary early-stage data for its experimental vaccine for the novel coronavirus, Moderna has finalized the plan for a Phase 3 test.
The study, set to begin next month, is targeting enrollment of about 30,000 volunteers,... Read more »
Verve Therapeutics aims to use gene editing to address heart attacks by targeting the liver, not the heart. And it wants to make its edits inside the patient. The startup’s approach raises a lot of questions. Verve has some answers now,... Read more »
Melinta Therapeutics and Tetraphase Pharmaceuticals, two antibiotics companies that have struggled separately, will now see if they have better luck together.
Morristown, NJ-based Melinta has reached a deal to acquire Tetraphase (NASDAQ: TTPH) for $39 million in cash up front.... Read more »
When fluid builds up in the brain faster than the body can absorb it, pressure builds sparking what’s called hydrocephalus. Surgery can address this condition, but the decades-old approach to relieving the cranial pressure caused by the fluid is susceptible to... Read more »
The $165 million bet that Sarepta Therapeutics placed on the gene therapy programs of Myonexus Therapeutics is starting to pay off with more early but encouraging clinical data from the deal’s most advanced program—a potential treatment for a type of limb-girdle... Read more »
Hearing loss can stem from a variety of reasons, but in rare cases it’s caused by genetic defects. Akouos is developing a gene therapy to address these problems and it’s planning an IPO to finance the first tests of its approach... Read more »
Race is not a topic that often comes up in pharmaceutical discussions but perhaps it should. Disease doesn’t discriminate by race, but health and economic disparities put some groups at higher risk than others. And yet clinical trials fail to reflect... Read more »
